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Guidelines recommend down‐titration of loop diuretics (LD) once euvolaemia is achieved. In outpatients 
with heart failure (HF), we investigated LD dose changes in daily cardiology practice, agreement with guideline 
recommendations, predictors of successful LD down‐titration and association between dose changes and 
outcomes. 
 
Methods and results 
 
We included 8130 HF patients from the ESC‐EORP Heart Failure Long‐Term Registry. Among patients 
who had dose decreased, successful decrease was defined as the decrease not followed by death, HF 
hospitalization, New York Heart Association class deterioration, or subsequent increase in LD dose. Mean age 
was 66 ± 13 years, 71% men, 62% HF with reduced ejection fraction, 19% HF with mid‐range ejection fraction, 
19% HF with preserved ejection fraction. Median [interquartile range (IQR)] LD dose was 40 (25–80) mg. LD 
dose was increased in 16%, decreased in 8.3% and unchanged in 76%. Median (IQR) follow‐up was 372 (363–
419) days. Diuretic dose increase (vs. no change) was associated with HF death [hazard ratio (HR) 1.53, 95% 
confidence interval (CI) 1.12–2.08; P = 0.008] and nominally with cardiovascular death (HR 1.25, 95% CI 
0.96–1.63; P = 0.103). Decrease of diuretic dose (vs. no change) was associated with nominally lower HF (HR 
0.59, 95% CI 0.33–1.07; P = 0.083) and cardiovascular mortality (HR 0.62, 95% CI 0.38–1.00; P = 0.052). 
Among patients who had LD dose decreased, systolic blood pressure [odds ratio (OR) 1.11 per 10 mmHg 
increase, 95% CI 1.01–1.22; P = 0.032], and absence of (i) sleep apnoea (OR 0.24, 95% CI 0.09–0.69; P = 
0.008), (ii) peripheral congestion (OR 0.48, 95% CI 0.29–0.80; P = 0.005), and (iii) moderate/severe mitral 




Diuretic dose was unchanged in 76% and decreased in 8.3% of outpatients with chronic HF. LD dose 
increase was associated with worse outcomes, while the LD dose decrease group showed a trend for better 
outcomes compared with the no‐change group. Higher systolic blood pressure, and absence of (i) sleep apnoea, 
(ii) peripheral congestion, and (iii) moderate/severe mitral regurgitation were independently associated with 
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Introduction  
Loop diuretics (LD) represent the mainstay of treatment for relieving congestion in patients with 
heart failure (HF).1,2 Approximately 80% of chronic HF (CHF) patients are treated with a diuretic, 
consistently in both HF with reduced (HFrEF) and preserved ejection fraction (HFpEF).3–5 Although 
diuretics have a class I recommendation in the guidelines, for patients with signs and symptoms of 
congestion, the level of evidence is ‘B’.6 One meta-analysis of small randomized trials suggests 
diuretics may improve outcomes,7,8 but observational studies have suggested a significant dose-
dependent association between LD use and adverse outcome in CHF.9–11 Higher LD doses may 
represent a marker of disease severity rather than a true risk factor,12 though this has also been 
identified in a small randomized study.13  
 
In addition, inappropriately high doses of LD might hamper up-titration of guideline-directed 
medical therapy (GDMT) and result in electrolyte disturbances, further neurohormonal activation, 
accelerated kidney function decline and symptomatic hypotension.14,15 Importantly, a post-hoc 
analysis of the CHAMPION trial indicated that mainly increases but also decreases in LD dose were 
the most common therapy changes related to improved outcome.16 Therefore, it is advised to use the 
lowest possible dose of diuretics and to adjust to individual needs, but in reality, often patients are 
kept on the same dosages for a long period of time.17,18 If patients are asymptomatic, the use of a LD 
could be discontinued in up to 60% of (selected) stable HF patients.19,20  
 
Nonetheless, data on real-world use of LD in patients with CHF and the extent that clinicians 
adhere to guideline recommendations are lacking.21 Moreover, although LD dose decrease is 
recommended, clinical data supporting that this strategy is feasible and beneficial are relatively 
limited.13,16,19,22 Finally, no clinical or laboratory predictors of LD down-titration success, possibly 
able to guide this process, have been recognized to date.20  
 
Thus, in outpatients with CHF we assessed: (i) LD dose changes in daily cardiology practice, (ii) 
the association between LD dose changes and GDMT changes, (iii) the agreement between daily 
cardiology practice and guideline recommendations regarding LD titration depending on volume 
status, (iv) the association between clinical characteristics and successful LD down-titration at 
baseline visit, and (v) the association between LD dose changes and 1-year outcomes. 
Methods  
Study design  
The European Society of Cardiology Heart Failure Long-Term (ESC-HF-LT) Registry was a 
prospective, multinational, multicentre, observational study of HF patients, conducted by the 
EURObservational Research Programme (EORP) in 337 cardiology centres from 33 ESC member 
countries. Data on subsequent hospital admissions and mortality were obtained at 12 months. The 
registry was approved by local ethical review boards according to the regulations of each 
participating country. All patients enrolled in the survey signed an informed consent, unless exempt 
by the local ethics committee. Further details on the ESC-EORP-HF-LT Registry are provided 
elsewhere.23,24  
 
In brief, site selection targeted a sample of hospitals of different levels of complexity, focusing 
on building up a network of centres representative of European reality. The number of centres in 
each country varied according to its size. Patients were managed according to the diagnostic and 
therapeutic interventions currently performed in each centre for patients with HF. No specific 
protocols or recommendations were provided during this observational study. Current guidelines for 
the management of HF were discussed during Investigator meetings, and doctors participating in the 
registry were encouraged to adhere to them. Several training meetings were organized for national 
coordinators and study investigators to assure consistency in data collection among participating 
centres. Furthermore, in each participating country, data sources were subjected to verification for 
a random sample of 5% of enrolled patients, by EORP monitors.  
 
For this analysis, outpatients with HF seen at the participating clinics between 22 March 2011 
and 30 November 2016 were included. The index date was defined as the baseline outpatient visit 
where baseline characteristics and diuretic dose changes were assessed: data on diuretics were 
recorded both prior to and after the index outpatient visit. Patients were included in the analysis if 
they received diuretics prior to and at end of the index visit, and excluded if they were missing data 
on diuretics at baseline or were receiving only a non-loop type diuretic (i.e. a diuretic other than 
furosemide, torasemide or bumetanide). LD doses were converted to equivalents of furosemide (20 
mg of torasemide = 1 mg of bumetanide = 40 mg of furosemide). The decision to exclude from the 
analysis patients that were not receiving a diuretic but were started on one during the index visit was 
based on the inability to recognize patients with first diagnosis of HF. We believe that these patients 
represent a different population compared with patients who are already receiving a LD. We take 
the same stance in regard to patients who were receiving LD prior to index visit and had their diuretic 
discontinued. Therefore, we only included patients who were receiving a LD both at beginning and 
end of index visit. 
Study parameters and outcome measures  
Loop diuretic dose change during baseline index visit was calculated based on the equation: LD 
dose after minus LD dose prior to index visit. LD dose change >0 was defined as dose increase, LD 
dose change <0 as dose decrease and LD dose change =0 as no change of dose. GDMT included 
beta‐blockers, angiotensin converting enzyme inhibitors (ACEi) and/or angiotensin receptor 
blockers (ARBs) and mineralocorticoid receptor antagonists (MRAs). Beta‐blockers doses are 
depicted in carvedilol equivalents. Other beta‐blockers were transformed to carvedilol equivalents 
based on the equation: 50 mg carvedilol = 10 mg bisoprolol = 200 mg metoprolol = 10 mg nebivolol; 
ACEi/ARB doses are depicted in captopril equivalents. Other ACEi/ARBs were transformed to 
captopril equivalents based on the equation: 150 mg captopril = 10 mg ramipril = 40 mg enalapril = 
40 mg lisinopril = 4 mg trandolapril = 16 mg perindopril = 40 mg fosinopril = 32 mg candesartan = 
320 mg valsartan = 150 mg losartan. MRA doses are depicted in spironolactone/eplerenone 
equivalents. 
 
Clinical stability was defined as the presence of all of the following: (i) symptoms corresponding 
to New York Heart Association (NYHA) classes I or II, and (ii) no history of HF hospitalization 
during the previous 6 months, and (iii) lack of all physical signs of congestion or hypoperfusion 
captured in the registry (pulmonary rales, S3 gallop, jugular venous pressure > 6 cm, pleural 
effusion, cold extremities, hepatomegaly, peripheral oedema) for which data were available. When 
information for each of these signs was not provided, the respective sign was considered absent. 
 
The outcomes studied were: (i) all‐cause mortality, (ii) cardiovascular (CV) mortality, (iii) HF 
mortality, and (iv) HF hospitalization during 1‐year following index outpatient visit. A visit 
12 months after the entry visit was mandatory per registry protocol in order to collect information 
on morbidity and mortality. A phone call could replace the clinical visit, in case of impossibility for 
the patient to reach clinical centres. Patients failing to attend clinical or phone visit were denoted as 
lost to follow‐up, as no other method, such as administrative data or other registries, was used for 
patient status acquisition. 
 
Furthermore, rates of and predictors of successful LD dose decrease at index visit were studied. 
Successful LD decrease was defined as the decrease of LD during index visit not followed by the 
composite of (i) death, (ii) HF hospitalization, (iii) NYHA class deterioration, or (iv) subsequent 
increase in LD dose during 12‐month follow‐up. 
Statistical analysis 
Baseline characteristics according to loop diuretic dose change 
Baseline characteristics of patients with LD dose decrease vs. increase vs. no‐change were 
presented as means ± standard deviation (SD), median (25th‐75th percentile), or counts (percentage) 
and compared with the Kruskal–Wallis test (non‐parametric) for continuous variables, and with the 
chi‐square test or Fisher's exact test (if chi‐square was not applicable) for categorical variables. 
 
 
Guideline‐directed medical therapy according to loop diuretic dose change 
Proportions of patients with LD dose decrease vs. increase vs. no‐change (i) receiving GDMT 
for HF and (ii) having GDMT initiated or up‐titrated were presented as counts (percentage) and 
compared with the chi‐square test. To investigate the association between LD and GDMT dose 
changes, a univariable logistic regression analysis was performed using GDMT changes as the 
dependent variable. 
Associations between baseline characteristics and successful loop diuretic dose decrease 
To identify independent predictors of successful LD decrease, univariable and multivariable 
logistic regressions were performed using successful LD dose decrease as the dependent variable. 
The 31 baseline variables tested as independent variables are marked with * in Table 1. The eight 
variables that were statistically significant in univariable analysis are marked with # in Table 1 and 
were included in the multivariable model to identify independent predictors of successful LD dose 
decrease. 
Associations between loop diuretic dose change at index visit and subsequent outcomes 
Plots of Kaplan–Meier curves for time to event for the three LD change groups were compared 
using the log‐rank test. In each analysis, subjects without the event were censored at the date of last 
contact or at a competing event. For time to CV death and time to HF death, subjects with unknown 
cause of death were not taken into account. To identify independent predictors of the study 
outcomes, univariable and multivariable Cox regression models were performed using study 
outcomes as the dependent variable. Baseline covariates which were significant at a level <0.05 and 
had at least 80% of available data were entered in a stepwise selection. Covariates remaining at the 
last step were included in the multivariable model. LD dose changes were entered in all multivariable 
models. Patients lost to follow‐up were not considered for Cox models and Kaplan–Meier curves. 
 
A two‐sided P ‐value of <0.05 was considered statistically significant. All analyses were 
performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA). 
Results 
From March 2011 to November 2016, 10 845 outpatients with CHF were included in the ESC‐
EORP‐HF‐LT Registry. After excluding 2715 patients who met the pre‐defined exclusion criteria, 
8130 outpatients were analysed (Figure 1). The baseline characteristics of the patients that were 






Table 1 Baseline characteristics of heart failure outpatients enrolled in the ESC Heart Failure Long-Term Registry, 


























Clinically stablea (%) 1495 (57) 0.0 270 (21) 
2614 
(43) 
284 (43) <0.001 0.78 
Age (years)*, # 
63.0 
± 13.7 
0.0 65.7 ± 13.6 
66.4 
± 12.7 
64.2 ± 14.1 0.003 <0.001 
Male sex* 185 (71) 0.0 899 (70) 
4433 
(72) 
474 (71) 0.52 0.55 
BMI (kg/m2)* 27.6 ± 4.8 1.0 28.7 ± 5.7 
28.2 
± 5.2 
27.7 ± 5.1 0.008 0.10 












Diastolic BP (mmHg)* 
75.7 
± 12.4 
0.5 74.8 ± 13.4 
72.9 
± 11.6 
72.2 ± 12.1 <0.001 0.06 
Heart rate (bpm)* 
71.3 
(15.5) 
0.1 79.5 ± 20.0 
72.2 
± 14.2 
72.4 ± 15.0 <0.001 0.66 
Peripheral congestion*, 
# 
191 (8.2) 1.5 481 (38) 
1084 
(18) 
127 (19) <0.001 0.43 
Pulmonary 
congestion* 
371 (58.2) 60.4 565 (76) 
1325 
(61) 
200 (66) <0.001 0.13 
Peripheral 
hypoperfusion* 
60 (2.6) 0.0 79 (6.2) 174 (2.8) 36 (5.4) <0.001 <0.001 
HF history with 
previous 
hospitalization* 
898 (35) 0.1 540 (43) 
2954 
(48) 
362 (54) <0.001 0.004 
HF history 
>12 months* 
1314 (72) 4.5 535 (52) 
3282 
(60) 
286 (46) <0.001 <0.001 
Primary HF aetiology*  0.0    <0.001 <0.001 
Dilated 
cardiomyopathy 
679 (26)  309 (24) 
1821 
(30) 
244 (36)   
Hypertension 261 (10)  121 (9.5) 455 (7.4) 59 (8.8)   
Ischaemic heart disease 1052 (41)  545 (43) 
2737 
(44) 
244 (36)   
Other 580 (23)  304 (24) 
1166 
(19) 
124 (19)   
CRT* 176 (7.5) 0.1 114 (9.1) 983 (16) 92 (14) <0.001 0.21 
ICD* 400 (17) 0.1 235 (19) 
1735 
(28) 
137 (21) <0.001 <0.001 
Smoking status* 350 (14) 0.0 168 (13) 617 (10) 76 (11) 0.003 0.27 
Diabetes* 595 (23) 0.0 460 (36) 
2120 
(34) 
231 (34) 0.52 0.95 
COPD* 258 (9.8) 0.0 184 (15) 945 (15) 108 (16) 0.59 0.57 
Sleep apnoea*, # 77 (3.3) 0.3 80 (6.3) 351 (5.8) 33 (5.0) 0.48 0.37 
Prior stroke/TIA* 216 (8.2) 0.0 119 (9.3) 606 (9.8) 60 (8.9) 0.69 0.47 
Chronic kidney 
dysfunction*, # 
244 (9.3) 0.0 304 (24) 
1325 
(22) 
155 (23) 0.13 0.33 
Hepatic dysfunction* 48 (2.0) 0.0 63 (4.9) 217 (3.5) 31 (4.6) 0.03 0.15 
Depression* 164 (6.3) 0.0 107 (8.4) 449 (7.3) 52 (7.8) 0.35 0.65 
Atrial 
fibrillation/flutter*, # 
409 (17) 6.1 365 (30) 
1340 
(23) 
134 (21) <0.001 0.14 
NYHA class  0.0    <0.001  
I–II 2141 (82)  718 (56) 
4528 
(73) 
483 (72)   
III–IV 463 (18)  561 (44) 
1649 
(27) 




3.2 37.7 ± 13.9 
36.7 
± 13.6 
36.0 ± 13.6 0.015 0.14 
Mitral regurgitation*, # 
moderate/severe 
406 (21) 14.5 500 (43) 
1681 
(33) 
179 (29) <0.001 0.09 
Haemoglobin (g/dL)*, 
# 
13.7 ± 1.8 15.9 12.8 ± 1.9 
13.3 
± 1.8 
13.2 ± 1.9 <0.001 0.33 





11.3 61.6 ± 23.6 
62.7 
± 26.8 













Beta‐blockers* 1945 (83) 0.0 872 (68) 
5411 
(88) 
573 (85) <0.001 0.11 
Beta‐blockers dose 
change at index visit 
(mg/day) 
– – 3.4 ± 10.5 1.8 ± 7.2 4.1 ± 11.0 <0.001 <0.001 
Beta‐blockers dose 
change from index 
visit to 12‐month FU 
(mg/day) 
– – 2.8 ± 14.5 
1.7 
± 13.3 
3.6 ± 25.6 0.002 0.136 
ACEi and/or ARBs* 1978 (84) 0.0 912 (71) 
5312 
(86) 
579 (86) <0.001 0.79 
ACEi and/or ARBs 
dose change at index 
visit (mg/day) 
– – 10.7 ± 31.2 
3.5 
± 19.4 
4.8 ± 30.0 <0.001 0.013 
ACEi and/or ARBs 
dose change from 
index visit to 12‐month 
FU (mg/day) 
 – 7.2 ± 41.4 
2.3 
± 37.8 
7.2 ± 37.1 <0.001 0.001 
MRAs* 758 (29) 0.0 521 (41) 
3820 
(62) 
430 (64) <0.001 0.25 
MRA dose change at 
index visit (mg/day) 
– – 5.7 ± 14.5 0.7 ± 7.0 0.2 ± 11.3 <0.001 0.051 
MRA dose change 
from index visit to 12‐
month FU (mg/day) 
 – 3.1 ± 18.5 
1.2 
± 15.2 
0.9 ± 14.4 0.042 0.955 
Diuretics        
Dose diuretics prior to 
visit (mg/day) 
– 0.0 55.5 ± 73.7 
59.1 
± 80.2 
75.7 ± 88.6 <0.001 <0.001 
Dose diuretics after 
visit (mg/day) 
– 0.0 74.6 ± 87.9 
59.1 
± 80.2 
48.9 ± 67.9 <0.001 <0.001 
Diuretic dose change at 
index visit (mg/day) 
– 0.0 









Values are presented as means ± standard deviation, median [25th–75th percentile], or n (%). Data are at the beginning of 
the visit, i.e. prior to any medication changes. 
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood 
pressure; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated 
glomerular filtration rate; FU, follow-up; HF, heart failure; ICD, implantable cardioverter-defibrillator; LD, loop diuretic; 
LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal 
pro-B-type natriuretic peptide; NYHA, New York Heart Association; TIA, transient ischaemic attack. 
Beta-blockers doses are depicted in carvedilol equivalents. Other beta-blockers were transformed to carvedilol equivalents 
based on the equation: 50 mg carvedilol = 10 mg bisoprolol = 200 mg metoprolol = 10 mg nebivolol. 
ACEi/ARB doses are depicted in captopril equivalents. Other ACEi/ARBs were transformed to captopril equivalents based 
on the equation: 150 mg captopril = 10 mg ramipril = 40 mg enalapril = 40 mg lisinopril = 4 mg 
trandolapril = 16 mg perindopril = 40 mg fosinopril = 32 mg candesartan = 320 mg valsartan = 150 mg losartan. MRA 
doses are depicted in spironolactone/eplerenone equivalents. 
LD dose change during baseline index visit was calculated based on the equation: LD dose after minus LD dose prior to 
index visit. LD dose change >0 was defined as dose increase, LD dose change <0 as dose decrease and LD 
dose change =0 as no change of dose. 
a Patients were considered as clinically stable if they fulfilled all of the following: (i) HF symptoms corresponding to 
NYHA functional classes I or II, (ii) no history of HF hospitalization during the previous 6 months, and (iii) lack of all 
physical signs of congestion or hypoperfusion captured in the registry (pulmonary rales, S3 gallop, jugular venous 
pressure>6 cm, pleural effusion, cold extremities, hepatomegaly, peripheral oedema). 
b NT-proBNP values were available in 33% of patients. 
* Baseline variables tested in univariable model. 
#Statistically significant variables in univariable analysis used for the multivariable model to identify predictors of 
successful LD dose decrease. 
** P-value for comparison between diuretic dose increased, stable and decreased groups. Patients included vs. excluded 
from the analysis differed significantly regarding all baseline characteristics except for sex distribution and use of 
beta-blockers and ACEi and/or ARBs. 




Figure 1 Flow-chart of patient selection. FU, follow-up; LD, loop diuretic 
Baseline characteristics and patterns of loop diuretic dose change 
Mean age was 66 ± 13 years, with 71% men. Mean left ventricular ejection fraction was 
37 ± 14% (62% HFrEF, 19% HF with mid‐range ejection fraction, 19% HFpEF). Mean ± SD and 
median [interquartile range (IQR)] daily dose of LD was 61 ± 81 and 40 (25–80) mg, respectively, 
and 3168 (40%) were stable and 4800 (60%) were unstable. During the index visit, 16% had dose 
of LD increased. Diuretic dose was increased in a significantly higher proportion of unstable 
compared with stable patients (P  < 0.001; Table 2 ). The general tendency was to keep the dose of 
LD unchanged (76%), but even more so in stable than in unstable patients (P  < 0.001). LD dose was 
reduced in few patients (8.3%), without, however, dose decrease showing interaction with clinical 
stability (P = 0.098; Table 2). 
Table 2. Loop diuretic dosing and clinical stability 
 
 Clinically stable Not Clinically stable Stability  not reported Total 
LD dose decrease 284 (9.0) 380 (7.9) 7 (4.3) 671 (8.3) 
LD dose increase 270 (8.5) 1003 (21) 6 (3.7) 1279 (16) 
LD dose stable 2614 (83) 3417 (71) 149 (92) 6180 (76) 
Total 3168 (100) 4800 (100) 162 (100) 8130 (100) 
 
Values are presented as n (%). 
LD, loop diuretic. 
Stability is defined as the presence of (i) New York Heart Association functional class I or II, (ii) no history of heart failure 
hospitalization during the previous 6 months, and (iii) lack of physical signs of congestion or hypoperfusion captured in the 
registry (pulmonary rales, S3 gallop, jugular venous pressure >6 cm, pleural effusion, cold extremities, hepatomegaly, 
peripheral oedema). 
 
Baseline clinical characteristics according to loop diuretic dose change 
Baseline characteristics per LD dose change are shown in Table 1. Patients in the LD dose 
increase group had significantly higher systolic blood pressure but otherwise had characteristics 
consistent with more severe HF compared with patients in the LD decrease and no‐change groups 
(Table 1). There was no difference in estimated glomerular filtration rate, but the LD increase group 
had higher left ventricular ejection fraction and higher rates of moderate/severe mitral and tricuspid 
valve regurgitation. Peripheral hypoperfusion was more common in the increase and decrease 
groups than in the no‐change group. 
Guideline‐directed medical therapy according to loop diuretic dose change 
At the beginning of index visit GDMT was less often used among patients who had LD dose 
increased compared with patients with LD maintenance and decrease (P  < 0.001; Table 1). 
Surprisingly, GDMT was up‐titrated slower (both at index visit and between index visit and follow‐
up) in patients with unchanged LD dose compared not only with patients with decreased LD dose 
but also with patients with increased LD dose (P  < 0.001 for all comparisons; Table 1). 
 
GDMT was initiated and/or up‐titrated in a significantly higher proportion of patients with LD 
dose increase at index visit compared with patients with LD dose decrease or maintenance 
(P  < 0.001; online supplementary Table S1 ), finding which was constant across patients in all 
ejection fraction groups (online supplementary Table S1 ). In univariable logistic regression, LD 
dose decrease [odds ratio (OR) 2.444, 95% confidence interval (CI) 2.074–2.880] and increase (OR 
3.929, 95% CI 3.468–4.452) were both associated with increased probability of GDMT 
initiation/up‐titration compared with LD dose maintenance (P  < 0.001; online 
supplementary Table S2 ). 
Predictors of successful loop diuretic dose decrease among patients with dose decrease at index 
visit 
Among 671 patients (8.3%) who had LD dose decreased, outcomes are reported in Table 3. 
Overall, in 271/559 patients (48%) LD dose decrease was successful. Higher systolic blood pressure 
(OR per 10 mmHg change 1.11, 95% CI 1.01–1.22; P = 0.032) and absence of (i) sleep apnoea (OR 
0.24, 95% CI 0.09–0.69; P = 0.008), (ii) moderate/severe mitral valve regurgitation (OR 0.57, 95% 
CI 0.37–0.87; P = 0.008), and notably (iii) peripheral congestion (OR 0.48, 95% CI 0.29–0.80; P = 
0.005) were associated with the LD dose decrease being successful (Table 4). 
Table 3. Incidence of the components of failed/unsuccessful loop diuretic dose decrease during 1‐year follow‐up among 671 







All‐cause death 21 (3.1) 51 (7.8) 
HF hospitalization 47 (7.0) 83 (13) 
NYHA deterioration 112 (17) 93 (17) 
LD dose increase 112 (17) 187 (34) 
Composite of death, HF hospitalization,  
NYHA deterioration, or LD dose increase 
112 (17) 288 (52) 
 
Values are presented as n (%). 
HF, heart failure; LD, loop diuretic; NYHA, New York Heart Association. 
 
 
Table 4. Associations between clinical characteristics and successful dose decrease among chronic heart failure outpatients 
with loop diuretic dose decrease at baseline 
 
Variable (potential predictor of successful 
diuretic dose decrease) 
Univariable Multivariable 
 OR (95% CI) P ‐value OR (95% CI) P ‐value 
Age (per year) 0.99 (0.98–1.00) 0.03   
Systolic BP (per 10 mmHg) 1.11 (1.02–1.21) 0.02 1.11 (1.01–1.22) 0.032 
Peripheral congestion (yes vs. no) 0.46 (0.30–0.73) <0.001 0.48 (0.29–0.80) 0.005 
Pulmonary congestion (yes vs. no) 0.94 (0.56–1.59) 0.83   
Peripheral hypoperfusion (yes vs. no) 0.77 (0.35–1.70) 0.51   
HF history with previous hospitalization (yes vs. 
no) 
0.97 (0.70–1.36) 0.88   
HF history >12 months (yes vs. no) 0.81 (0.57–1.14) 0.23   
Primary aetiology (IHD vs. non‐IHD) 0.89 (0.63–1.25) 0.50   
Diabetes (yes vs. no) 0.75 (0.53–1.07) 0.11   
Sleep apnoea (yes vs. no) 0.38 (0.16–0.92) 0.03 0.24 (0.09–0.69) 0.008 
Chronic kidney dysfunction (yes vs. no) 0.65 (0.44–0.97) 0.04   
Rhythm atrial fibrillation/flutter vs. sinus 0.53 (0.34–0.83) 0.005   
EF (%) 1.00 (0.99–1.02) 0.43   
Mitral regurgitation moderate/severe (yes vs. no) 0.53 (0.36–0.78) 0.001 0.57 (0.37–0.87) 0.008 
Haemoglobin (g/dL) 1.12 (1.01–1.23) 0.03   
Beta‐blockers (prior to visit) (yes vs. no) 1.30 (0.80–2.11) 0.29   
ACEi and/or ARBs (prior to visit) (yes vs. no) 1.52 (0.93–2.47) 0.09   
MRAs (prior to visit) (yes vs. no) 1.24 (0.88–1.76) 0.22   
 
ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CI, confidence 
interval; EF, ejection fraction; IHD, ischaemic heart disease; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, 
mineralocorticoid receptor antagonist; OR, odds ratio. 
An OR > 1.0 means the variable was associated with successful dose decrease. 
Cohort size: n = 559 patients with complete data on variables to assess success of dose decrease. All variables tested in the 
univariable logistic regression analysis are depicted with * in Table 1. 
Association between diuretic dose change and outcomes 
During a median (IQR) follow‐up of 372 (363–419) days, outcomes were available for 
7899/8130 patients (97%), with 757 deaths (9.6%) [385 CV deaths (51% of all), 257 HF deaths 
(34% of all)], 2344 patients rehospitalized at least once (30%), and 1095 rehospitalized at least once 
for HF (15%). Detailed information on data availability and outcomes in the overall cohort and 
across the three LD groups is shown in online supplementary Table S3 . The cumulative rate of all‐
cause death was 14% for LD dose increase, 7.8% for LD dose decrease and 8.9% for no‐change LD 
dose groups (P  < 0.001; Figure 2A ). The respective rates of CV death were 7.3%, 3.2% and 4.7% 
(P  < 0.001; Figure 2B ), of HF death 5.4%, 2.2% and 3.1% (P  < 0.001; Figure 2C ) and of the 
composite of all‐cause death or HF hospitalization 26.6%, 17.7% and 19.0% 





Kaplan–Meier curves for the three study groups with (A ) all‐cause death, (B ) cardiovascular death, (C ) heart failure death, 
and (D ) all‐cause death or heart failure hospitalization as the endpoint. FU, follow‐up. 
The adjusted hazard ratios (HR) for 1‐year outcomes are depicted in Figure 3, whereas the 
results of the multivariable Cox regression analyses for all study outcomes in online 
supplementary Table S4 . LD dose increase (vs. no change) was associated with increased risk for 
HF death (HR 1.53, 95% CI 1.12–2.08; P = 0.008) and nominally with increased risk of CV death 
(HR 1.25, 95% CI 0.96–1.63; P = 0.103). These associations were pronounced and statistically 
significant among patients with HFpEF (HR 2.472, 95% CI 1.188–5.143; P = 0.015 for HF death; 
and HR 2.037, 95% CI 1.090–3.810; P = 0.026 for CV death; online supplementary Table S5 ). 
Conversely, decrease of diuretic dose (vs. no change) was nominally associated with a lower CV 
(HR 0.620, 95% CI 0.38–1.00; P = 0.052) and HF mortality (HR 0.59, 95% CI 0.33–1.07; P = 
0.083). 
 
Loop diuretic dose increase (vs. decrease) was independently associated with a twofold risk of 
CV death (HR 2.01, 95% CI 1.19–3.39; P = 0.009), a 2.6 times higher risk of HF death (HR 2.57, 
95% CI 1.37–4.83; P = 0.003), and nominally with HF hospitalization (HR 1.31, 95% CI 0.99–




Among all patients, adjusted hazard ratios for all‐cause death, cardiovascular (CV) death, heart failure (HF) death and HF 
hospitalization according to loop diuretic (LD) dose change. CI, confidence interval. 
Discussion 
In this large population of HF patients across 33 ESC countries, (i) LD dose at an outpatient visit 
was down‐titrated in only 8.3% overall and in only 9% of clinically stable patients; (ii) LD dose 
increase and decrease were associated with increased probability of GDMT initiation/up‐titration 
both at index visit and during follow‐up compared with LD dose maintenance; (iii) overall, increase 
of LD dose was associated with increased risk of CV and especially HF events, while decrease of 
LD dose was associated with decreased risk for CV and HF events; (iv) among patients with LD 
dose decrease, this was ‘successful’ in half, and (v) higher systolic blood pressure, and absence of 
sleep apnoea, peripheral congestion and moderate/severe mitral regurgitation independently 
predicted successful LD dose decrease. 
Patterns of loop diuretic dose change 
The rate of LD dose decrease was disappointingly low but in line with previous smaller 
studies,12, 25 highlighting a discordance between ‘real‐world’ HF patterns and guidelines. This is 
potentially attributable to the paucity of evidence guiding use of diuretics in HF. 
Guideline‐directed medical therapy according to loop diuretic dose change 
At baseline patients in the LD increase group had higher rates of clinical instability (higher 
NYHA classes, more signs/symptoms of congestion, higher levels of natriuretic peptides) and lower 
rates of receipt of GDMT, findings which are expected and in line with current knowledge.26, 27 The 
surprising finding of our analysis was that LD dose increase did not seem to hinder GDMT initiation 
and/or up‐titration. Contrary, in our analysis LD dose maintenance was associated with less frequent 
and slower up‐titration of GDMT (both at index visit and between index visit and follow‐up) 
compared not only with patients with decreased LD dose but also with patients with increased LD 
dose. Interestingly, patients with LD dose increase were also more likely to have GDMT initiation 
and/or up‐titration even compared with patients with LD dose decrease. These results seemingly 
contradict recently published findings from the BIOSTAT‐CHF study, according to which higher 
doses of LD hinder up‐titration of ACEi in HFrEF patients.28 However, a reasonable explanation for 
this difference lies in the design of the two studies: BIOSTAT‐CHF was a prospective study aiming 
at achieving optimal GDMT among HFrEF patients who were undertreated, while ESC‐HF‐LT is 
merely a registry which captures patterns of HF medication use in a real‐life setting. In this direction, 
our findings strongly indicate, though do not prove, that clinicians' inertia rather than patient's 
intolerability or volume status is the main barrier to GDMT optimization in HF outpatients in real 
life. 
Association between diuretic dose change and outcomes 
Loop diuretic increase was associated with worse, whereas decrease with better clinical 
outcomes compared to maintenance. This of course may be simply a risk marker of greater HF 
severity among patients who have dose increased and/or kept stable, but uniquely the registry 
contains extensive data on variables that may affect both diuretic dosing and outcomes, including 
data on left and right‐sided congestion, perfusion, clinical stability, HF severity and comorbidities, 
and clinical and laboratory variables. We performed extensive adjustment for these and other 
variables, and the risk associated with LD dose increase (vs. maintenance) remained approximately 
50% higher for HF death and approximately 10–25% increased for other outcomes. On the other 
hand, LD dose decrease (vs. maintenance) also presented with a trend for 40% lower CV and HF 
death. This magnitude of risk excess after extensive adjustment suggests that it is likely, although 
not proven, that increase as well as maintenance of LD dose are risk markers for more severe HF 
but also true risk factors for worse outcomes. 
 
These findings are consistent with previous reports that high LD doses are associated with 
increased risk for death and other adverse outcomes.9-12, 29-33 Interestingly, Mielniczuk et 
al .12 observed that the association between LD and adverse outcome was rendered insignificant after 
adjustment for clinical stability; however, in our study the associations between dose change and 
outcomes were independent of clinical stability and other factors. Furthermore, a major limitation 
of previous analyses was that LD doses and not dose change were studied. Apart from a single 
retrospective study,25 and a small randomized study, in which HF patients were randomly assigned 
to either maintenance or dose decrease,13 the association between LD dose change and outcomes is 
here for the first time studied and reported in such a large population of unselected HF outpatients. 
Successful loop diuretic dose decrease and its predictors 
Loop diuretic dose decrease was successful through 1‐year follow‐up in half of patients in whom 
it was attempted. That it was unsuccessful in the other half does not mean it should not be attempted 
given the more favourable outcomes of patients with LD decrease overall. Previous smaller studies 
suggest that down‐titration of LD dose in selected stable patients is feasible in 58–95%, but these 
did not include all patients at outpatient visits and are less generalizable.13, 18, 22, 34, 35 Furthermore, 
previous small studies could not identify independent predictors of successful dose 
decrease.18, 20, 35 Understanding such predictors may inform the selection of the appropriate patient 
for dose decrease, thus increasing this potentially beneficial intervention. Thus, importantly, for the 
first time, we have demonstrated independent predictors for successful LD dose decrease: higher 
blood pressure and absence of sleep apnoea, peripheral congestion and moderate/severe mitral valve 
regurgitation. Volume overload in HF leads to left ventricular dilatation, progressive remodelling, 
and aggravates the severity of secondary mitral regurgitation and impairs left atrial function, while 
decongestion may lead to relative reversal of these phenomena.36, 37 Thus, LD dose reduction in 
patients with more severe secondary mitral regurgitation may be more difficult to achieve. Notably, 
absence of peripheral congestion was strongly and independently associated with successful LD 
dose decrease (adjusted HR 0.48), whereas absence of pulmonary congestion, hypoperfusion, and 
other markers of HF severity were not. A recent analysis from the ESC‐HF‐LT Registry showed that 
31% of HF patients had residual congestion at hospital discharge, and that this was associated with 
a 46% increased risk of death post‐discharge.38 Taken together, our findings suggest that LD dose 
decrease should be attempted more often in general but should be done with caution or not at all in 
patients with residual peripheral congestion. Thus, in euvolaemic patients with HF we should 
perhaps use less diuretics, whereas in patients with peripheral congestion we should perhaps 
use more diuretics. In the light of the favourable effects that sodium–glucose co‐transporter‐2 
inhibitors and sacubitril/valsartan demonstrate in the outcomes of patients with HF,39, 40 combined 
with their postulated mechanisms of action and their potential to mediate LD dose decrease,41, 42 their 
use must be encouraged in all suitable HF patients. In any case, the paucity of strong evidence 
guiding diuretic treatment in HF is unequivocal, and the design and execution of studies to test the 
feasibility and effects of different diuretics and different dosing regimens are urgently needed. 
Limitations 
The study included patients seen in cardiology units only. HF diagnosis and cause of death were 
based on treating physicians and not adjudicated. LD use is a marker of LD need, which is a marker 
of HF severity. Thus, the association between LD changes and outcomes is expected. We excluded 
patients enrolled in the registry at HF hospitalization but cannot exclude that LD increases were 
appropriate interventions for worsening HF and congestion in the outpatient setting. While signs and 
symptoms are subjective and unreliable, they add important clinical information and are rarely 
available in registry and cohort studies. We included all patients with diuretics at baseline, but 
clinically, the LD increase group likely represents a phenotype with a clear worsening of HF, 
whereas LD decrease and LD unchanged are likely more similar. Furthermore, due to the complexity 
of the analyses, the multiple comparator groups, and the lack of information on non-CV outcomes, 
we were  not able to perform sensitivity or consistency analyses using for example propensity scores 
or falsification outcomes (e.g. non-CV ‘negative control’ outcomes). Thus, the outcome analyses 
should be interpreted with caution. Nevertheless, we do raise the possibility that some of the reduced 
risk with LD decrease and increased risk with LD increase actually represent, at least in part, a causal 
harmful effect of conventional LD, such as through neurohormonal activation. Furthermore, the 
reasons underlying changes or lack of change in LD dose are unknown and can only be postulated. 
Finally, LD dose change was studied at a single time-point and not over time. This means that we 
have captured data on two time points, which notably are far apart from each other, therefore 
dynamic changes over time could not be accounted for. This is an important limitation, as we do not 
know if and how many changes patients had. Moreover, the fact that outcome data were only 
available at 1 year after the index visit – when LD dose changes were recorded – also weakens the 
associations between LD dose change and outcomes. A relatively small, but clinically meaningful, 
proportion of patients (∼3%) were lost to follow-up. Nevertheless, this is the largest and most 
rigorously adjusted study of diuretic dosing to date. 
Conclusion  
At HF outpatient visits, LD dose was down-titrated in only 8.3% overall and in only 9.0% of 
clinically stable patients, unchanged in 76% and up-titrated in 16% overall. Maintenance of LD dose 
was associated with decreased likelihood of initiating and/or up-titrating GDMT compared with LD 
dose increase and decrease, possibly denoting clinicians’ inertia as the reason for sub-optimal 
GDMT dosing in real life. Increase of LD dose was associated with worse outcomes, while LD dose 
decrease with better outcomes. After rigorous adjustment for multiple factors, a strong association 
remained, suggesting, but not proving, that failure to appropriately reduce diuretic dose among 
outpatients may potentially be causing worse outcomes. However, residual confounding cannot be 
excluded. Among patients who underwent LD dose decrease, this was ‘successful’ in half. Higher 
systolic blood pressure independently predicted successful diuretic dose decrease. In contrast, 
peripheral (but not pulmonary) congestion as well as sleep apnoea and mitral regurgitation 
independently predicted unsuccessful LD dose decrease. Taken together, these findings suggest that 
LD dose decrease should be attempted more often in stable euvolaemic patients, whereas in patients 
with peripheral congestion, LD should not be reduced and perhaps increased. This hypothesis 
warrants testing in randomized trials. 
Supplementary Information  
Additional supporting information may be found online in the Supporting Information section at 
the end of the article.  
Table S1. Rates of loop diuretic dose changes among patients with guideline-directed medical 
therapy changes. Data presented in overall cohort and stratified by ejection fraction group (HFrEF, 
HFmrEF and HFpEF).  
Table S2. Univariable logistic regression analysis with increase/ initiation in guideline-directed 
medical therapy as dependent and diuretic dose change as independent variables.  
Table S3. Data availability and rates of 12-month study outcomes among the overall study cohort 
and across the three groups of loop diuretic dose change. Table S4. Multivariable Cox regression 
analyses for study outcomes.  
Table S5. Multivariable Cox regression analyses for the study outcomes stratified by ejection 
fraction group. 
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